WINDLAS · Health Care · 2026-08-07

Windlas Biotech Ltd

4.6WatchEven +1.3Stage 2 · wk 4In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹882.9
+1.04% today
₹1,822 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.

Visit company website →
P/E (TTM)
26.3
Forward —
Earnings Growth (YoY)
-2.6%
Revenue +17.7%
ROE
+12.2%
Profit margin +7.4%
Dividend Yield
0.70%
P/B 3.2
vs 52W High
-17.6%
₹705.8 lo₹1,070.8 hi
17.6% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
7.9%
200 DMA: ₹818.1 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
1.28x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.7% vs MA50 +2.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #67 of 79 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #44 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 25w
S2 61w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 25w → S3 2w → S2 61w → S3 11w → S4 2w → S1 2w → S2 6w → S3 1w → S4 7w → S1 4w → S2 5w → S3 4w → S4 13w → S1 3w → S4 7w → S1 10w → S2 4w current
Total tracked: 168 weeks across 17 stage runs.
1M
+6.9%
3M
+7.3%
6M
+3.2%
YTD
+14.5%
1Y
-11.4%
Scan Membership
Prop Scan
Latest: 2026-08-07
Breakout Watch
Latest: 2026-07-13
23 appearances in last 60 days. First seen: 2025-05-07.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 4 · Vol —x
2026-08-06S2
Wk 4 · Vol —x
2026-08-05S2
Wk 4 · Vol —x
2026-08-04S2
Wk 4 · Vol —x
2026-08-03S2
Wk 4 · Vol —x
2026-07-31S2
Wk 3 · Vol —x
2026-07-30S2
Wk 3 · Vol —x
2026-07-29S2
Wk 3 · Vol —x
2026-07-28S2
Wk 3 · Vol —x
2026-07-27S2
Wk 3 · Vol —x
2026-07-24S2
Wk 2 · Vol —x
2026-07-23S2
Wk 2 · Vol —x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹844.7
200 DMA
₹818.1
52W High
₹1,070.8
52W Low
₹705.8
5D Low
₹856.9
Resistance levels (recent highs)
20d High
₹882.9
60d High
₹882.9
120d High
₹894.6
250d High
₹1,070.8
Next resistance
+1.3%
to 120d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.